Formulation Development
TOLREMO Therapeutics Receives Two FDA Fast Track Designations
TOLREMO therapeutics AG recently announced its lead candidate, TT125-802, received two Fast Track designations from the US FDA for the treatment of non-small cell lung…
Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy
Wugen, Inc. recently announced the closing of $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital,…
TREOS Bio Partners With Charité Berlin & Junshi Biosciences to Launch Pivotal Phase 2 Clinical Trial in Refractory MSS Colorectal Cancer
TREOS Bio Ltd. recently announced the execution of clinical collaboration agreements with Charité – Universitätsmedizin Berlin and Junshi Biosciences for the initiation of OBERTO-202, a…
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
MannKind Corporation recently announced United Therapeutics Corporation has exercised its option—granted under the companies’ 2018 license and collaboration agreement—to develop a second dry powder inhalation…
Moleculin Issues New Positive AML Overall Survival Data
Moleculin Biotech, Inc. recently announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as Ara-C and…
Bio-Rad Expands Range of StarBright Dyes to Enhance Panel Design Capabilities for Spectral Flow Cytometry
Bio-Rad Laboratories, Inc. recently announced the introduction of a new range of StarBright Dyes, providing greater choice and flexibility for spectral flow cytometry in immunology…
Cereno Scientific Granted FDA Fast Track Designation for CS1 in Rare Disease Pulmonary Arterial Hypertension
Cereno Scientific recently announced the US FDA has granted Fast Track designation to its lead program, CS1, for the treatment of pulmonary arterial hypertension (PAH).…
Hongene to Supply exNA Oligonucleotide Technology Under New Licensing Deal
Hongene Biotech Corporation recently entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and…
Scenic Enters License & Research Agreement With Alnylam
Scenic Biotech recently announced a license and research agreement with Alnylam Pharmaceuticals, Inc. to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.…
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Allarity Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The…
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery
Clearside Biomedical, Inc. recently announced its SCS delivery platform and CLS-AX program will be highlighted in multiple presentations at the 25th EURETINA Congress from September…
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
CDT Equity Inc. recently announced it has successfully identified a new biological target and novel therapeutic indication for its lead program, AZD1656 (and its derivatives),…
Newly Published Paper Unveils Breakthrough Enzyme That Expands Possibilities for Peptide Drug Discovery
A team of researchers from the University of Utah and Sethera Therapeutics has uncovered a powerful new way to build more stable and drug-like peptides,…
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth & Emerging as a Patient-Centric Leader in Cardiometabolic & Lung Diseases
MannKind Corporation and scPharmaceuticals Inc. recently announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals. This proposed acquisition marks MannKind’s strategic…
Artelo Biosciences Announces New Data From Initial Food Effect Investigation With a Novel Non-Opioid Treatment Candidate for Persistent Pain
Artelo Biosciences, Inc. recently announced encouraging results from its preliminary food effect evaluation with ART26.12. This assessment was conducted as a part of the successful single…
Immuneering Announces Clinical Supply Agreement With Lilly to Evaluate Atebimetinib in Combination With Olomorasib
Immuneering Corporation recently announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports…
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
HCW Biologics Inc. recently announced its scientists have successfully developed second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its novel…
Biofrontera Announces Last-Patient-Out in Phase 2b Study of Ameluz Topical Gel for the Treatment of Moderate-to-Severe Acne Vulgaris
Biofrontera Inc. recently announced the final patient in its Phase 2b clinical trial evaluating Ameluz (aminolevulinic acid hydrochloride) for the treatment of moderate-to-severe acne vulgaris…
Larkspur Biosciences Announces Discovery of a First-in-Class Degrader of the Lipid Kinase PIP4K2C for the Treatment of Microsatellite Stable Colorectal Cancer
Larkspur Biosciences recently announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer…
Advanz Pharma & Alvotech Receive European Approval for Mynzepli, Biosimilar to Eylea
Alvotech and Advanz Pharma Holdco Limited recently announced the European Commission has approved Mynzepli as a biosimilar to Eyle (aflibercept), in a pre-filled syringe and…
